The first FDA-approved teriparatide alternative to Forteo®*

Discover a lower cost option for your patients

Savings based on WAC.

Teriparatide Injection delivers proven clinical experience and affordability to help your patients at high risk for fracture increase bone density. Not to be used more than 2 years.

Alvogen’s Teriparatide Injection is an FDA-approved treatment option comparable to Forteo®

  • Active ingredient


  • Strength

    20 mcg/day

  • Dosing

    28 days

  • Indications

    3 patient populations

  • Administration

    single-patient-use multi-dose pen

* Not automatically substituted for Forteo.
Forteo is a registered trademark of Eli Lily and Company, which has no affiliation with Alvogen.

Proven Clinical Experience

Teriparatide Injection significantly reduced the risk of osteoporotic fractures, while increasing bone mineral density (BMD), in postmenopausal women at high risk for fracture, as compared to placebo.1§

  • 65% Relative risk reduction in new vertebral fractures (5.0% vs. 14.3%, P<0.001)1
  • 53% Relative risk reduction in new nonvertebral fractures (2.6% vs. 5.5%, P<0.05)1
  • Significantly increased BMD at the lumbar spine, femoral neck, total hip, and total body (P<0.05)1

§ Study Design: A multicenter, prospective, double-blind study in 1,637 postmenopausal women with osteoporosis, of whom 90% had a spine fracture. Patients received once-daily 20-mcg dose of Teriparatide Injection (n=541) or placebo (n=544). Patients were treated for median time of 19 months, and maximum of 24 months. All women took calcium and vitamin D daily.


  1. Teriparatide Injection [Prescribing Information]. Morristown, NJ: Alvogen, Inc.; 2019.
  2. Forteo [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company; 2012.
  3. Data on file.

Here to help your patients save:

The Alvogen Teriparatide Injection Savings Program

We know that cost is an important consideration when selecting a treatment option for a chronic condition

Learn more
a rep